RO7017773

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Autism Spectrum DisorderAutism Spectrum Disorder (ASD)Healthy Volunteers

Phase 1

Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513

CompletedNCT03507569

Hoffmann-La RocheAutism Spectrum Disorder

Start: 2018-04-24End: 2018-06-22Updated: 2019-09-30

A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants

CompletedNCT03774576

Hoffmann-La RocheHealthy Volunteers

Start: 2018-12-17End: 2019-03-14Updated: 2020-05-07

Phase 2

A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

CompletedNCT04299464

Hoffmann-La RocheAutism Spectrum Disorder (ASD)

Start: 2021-03-31End: 2024-05-15Updated: 2025-01-28